How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment

By on    Pharma Industry News  

How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment

Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. This strategic move secures Johnson & Johnson the exclusive global rights to NM26, a pioneering bispecific antibody set to advance into Phase 2 trials for treating atopic dermatitis (AD). NM26 […]

Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate

By on    Pharma Industry News  

Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate

In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of Numab Therapeutics, gaining global rights to an investigational bispecific antibody, NM26. The deal, valued at approximately $1.25 billion, is poised to transform treatment paradigms in atopic dermatitis (AD) and potentially […]